ATE422505T1 - Aktive subfragmente von human histidine-rich glycoprotein - Google Patents

Aktive subfragmente von human histidine-rich glycoprotein

Info

Publication number
ATE422505T1
ATE422505T1 AT04749127T AT04749127T ATE422505T1 AT E422505 T1 ATE422505 T1 AT E422505T1 AT 04749127 T AT04749127 T AT 04749127T AT 04749127 T AT04749127 T AT 04749127T AT E422505 T1 ATE422505 T1 AT E422505T1
Authority
AT
Austria
Prior art keywords
subfragments
angiogenic
human
present
hrgp
Prior art date
Application number
AT04749127T
Other languages
English (en)
Inventor
Welsh Lena Claesson
Anna-Karin Olsson
Original Assignee
Innoventus Project Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innoventus Project Ab filed Critical Innoventus Project Ab
Application granted granted Critical
Publication of ATE422505T1 publication Critical patent/ATE422505T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT04749127T 2003-07-07 2004-07-05 Aktive subfragmente von human histidine-rich glycoprotein ATE422505T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48518503P 2003-07-07 2003-07-07
SE0301988A SE0301988D0 (sv) 2003-07-07 2003-07-07 Active subfragment of an endogenous peptide

Publications (1)

Publication Number Publication Date
ATE422505T1 true ATE422505T1 (de) 2009-02-15

Family

ID=27731109

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04749127T ATE422505T1 (de) 2003-07-07 2004-07-05 Aktive subfragmente von human histidine-rich glycoprotein

Country Status (9)

Country Link
US (1) US7662388B2 (de)
EP (1) EP1648929B1 (de)
JP (1) JP2007528710A (de)
AT (1) ATE422505T1 (de)
AU (1) AU2004253842A1 (de)
CA (1) CA2531240A1 (de)
DE (1) DE602004019420D1 (de)
SE (1) SE0301988D0 (de)
WO (1) WO2005003162A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2553464A4 (de) 2010-04-01 2014-04-02 Karolinska Inst Innovations Ab Befruchtungsprognose und -förderung
US9696321B2 (en) 2012-06-06 2017-07-04 National University Corporation Okayama University Therapeutic agent, method of treatment and method for predicting the severity of systemic inflammatory response syndrome (SIRS), diseases caused or accompanied by neutrophil activation
WO2013183494A1 (ja) 2012-06-06 2013-12-12 国立大学法人 岡山大学 好中球活性化に起因する疾患の治療薬、治療方法及び検査方法
JPWO2019230509A1 (ja) 2018-05-31 2021-06-24 国立大学法人 岡山大学 活性酸素の産生抑制剤及び／又は消去促進剤
CN112512547A (zh) 2018-06-28 2021-03-16 国立大学法人冈山大学 嗜中性粒细胞吞噬能力增强剂
WO2024086400A1 (en) * 2022-10-17 2024-04-25 Research Institute At Nationwide Children's Hospital Macrophage polarizing oncolytic herpes simplex virus for cancer therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020037517A1 (en) * 1993-05-28 2002-03-28 Hutchens T. William Methods for sequencing biopolymers
US20010041670A1 (en) 1999-12-06 2001-11-15 Ronit Simantov Thrombospondin-binding region of histidine-rich glycoprotein and method of use
WO2002076486A2 (en) 2001-02-05 2002-10-03 Innoventus Project Ab Histidine-rich glycoprotein
WO2002064621A2 (en) * 2001-02-14 2002-08-22 Attenuon, Llc Histidine proline rich glycoprotein (hprg) as an anti-angiogenic and anti-tumor agent
EP1575525A4 (de) * 2002-03-15 2008-04-02 Attenuon Llc Zelloberflächen-tropomyosin als target für die hemmung der angiogenese

Also Published As

Publication number Publication date
JP2007528710A (ja) 2007-10-18
EP1648929A2 (de) 2006-04-26
US7662388B2 (en) 2010-02-16
CA2531240A1 (en) 2005-01-13
WO2005003162A3 (en) 2005-03-10
DE602004019420D1 (de) 2009-03-26
SE0301988D0 (sv) 2003-07-07
AU2004253842A1 (en) 2005-01-13
WO2005003162A2 (en) 2005-01-13
EP1648929B1 (de) 2009-02-11
US20080125355A1 (en) 2008-05-29

Similar Documents

Publication Publication Date Title
ATE549028T1 (de) Stabile analoga von glp-1
EP1446115A4 (de) Cyanoalkylamino-derivate als protease-hemmer
SE0201980D0 (sv) Novel compounds
ATE348096T1 (de) C-terminal modifizierte oxamyl dipeptide als inhibitorse von der ice/ced-3 familie von cystein proteasen
DE602004032107D1 (de) Nell-peptidexpressionssysteme und knochenbildende aktivität des nell-peptids
DE60332358D1 (de) Protease-resistente modifizierte interferon alpha polypeptide
MXPA03000626A (es) Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de la hepatitis c.
UY27585A1 (es) Cis - imidazolinas
DE69938786D1 (de) Die verwendung von peptiden von il-2 und peptid-derivaten als therapeutische wirkstoffe
DK0409472T3 (da) Knoglemorfogenetisk protein
EP1767546A4 (de) Ein die angiogenese inhibierendes chimäres protein und dessen verwendung
BG101867A (bg) Бензотиазиндиоксиди като антагонисти на ендотелин
MX2020013296A (es) Composiciones que contienen inhibidor de proteasa recombinante, metodos para producir las mismas y usos de las mismas.
DE60331546D1 (de) Verwendung von aspartic proteasen in den bereichen kosmetik und behandlung
BR0211761A (pt) depsipeptìdeos e processos para preparar os mesmos
DE60306934D1 (de) Verwendung von Nitrilenverbindungen als Arztneimittel
HRP20050585A2 (en) Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereof
ATE353336T1 (de) Neues peptid mit angiotensinkonvertase hemmender wirkung
DE602004019420D1 (de) Aktive subfragmente von human histidine-rich glycoprotein
DE69840497D1 (de) Verwendung von Aplidine zur Behandlung von kardiovaskulären Erkrankungen
SE0301431D0 (sv) Novel antimicrobial peptides
ATE308335T1 (de) Histidine-rich glycoprotein (hrgp) zur hemmung der angiogenese
HRP20050024A2 (en) Pegylated t20 polypeptide
DE60031422D1 (de) Peptidanaloge als selektive inhibitoren der thrombinaktivierung des durch protease aktivierten rezeptors
ATE449790T1 (de) Rekombinante gelatinepartikel für die zelladhäsion

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties